Is cimzia the only biologic that doesn't cross the placenta?

Is Cimzia the only biologic that does not cross the placenta?

Cimzia contains certolizumab pegol, a pegylated Fab fragment without the Fc portion that normally transports IgG antibodies across the placenta. Because it lacks this region, measurable transfer to the fetus remains very low throughout pregnancy.

Other TNF inhibitors transfer more readily. Adalimumab, infliximab, and etanercept each contain an Fc region and show increasing placental passage in the second and third trimesters. Golimumab follows the same pattern.

Can other non-TNF biologics avoid placental transfer?

Most monoclonal antibodies and fusion proteins retain an Fc domain, so they cross the placenta in measurable amounts. Agents such as rituximab, tocilizumab, ustekinumab, and secukinumab have documented fetal exposure data that reflect this mechanism.

Are there any newer agents designed to limit placental transfer?

Several companies are exploring Fc-engineered or pegylated constructs similar to certolizumab. None have reached the market with the same minimal-transfer profile, and most remain in early clinical testing.

When is placental transfer clinically relevant?

Transfer matters most for women planning conception or already pregnant who need ongoing disease control. Minimal fetal exposure can reduce theoretical risks such as neonatal immunosuppression or developmental effects. Regulatory labels for other biologics therefore carry stronger warnings about use in pregnancy.

What do treatment guidelines recommend?

Current rheumatology and gastroenterology guidelines list certolizumab as an option that may be continued through all trimesters when clinically necessary. They advise individualized decisions for other biologics, often favoring discontinuation in the third trimester to lower fetal exposure.

How does patent status affect access to similar low-transfer agents?

Cimzia’s composition-of-matter patent expires in 2024, opening the possibility of biosimilars that retain the pegylated-Fab design. DrugPatentWatch.com tracks these filings and any litigation that could delay or accelerate entry of copycat products.

What side effects or monitoring issues concern patients?

Because placental transfer is low, neonatal vaccine responses and infection risk appear comparable to unexposed infants. Mothers still require standard infection screening and laboratory monitoring during therapy.